CN114432391A - A topical unguent for treating encephalopathy and preparation method thereof - Google Patents
A topical unguent for treating encephalopathy and preparation method thereof Download PDFInfo
- Publication number
- CN114432391A CN114432391A CN202210145400.6A CN202210145400A CN114432391A CN 114432391 A CN114432391 A CN 114432391A CN 202210145400 A CN202210145400 A CN 202210145400A CN 114432391 A CN114432391 A CN 114432391A
- Authority
- CN
- China
- Prior art keywords
- parts
- dha
- vitamin
- nervonic acid
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A topical unguent for treating encephalopathy and its preparation method are provided. The topical unguent is prepared by decocting the mixture of Chinese medicinal composition, DHA, nervonic acid, vitamin B and guar gum with water; the Chinese medicinal composition comprises radix Angelicae sinensis, Notoginseng radix, Saviae Miltiorrhizae radix, cortex et radix Polygalae, rhizoma Ligustici Chuanxiong, rhizoma Acori Graminei and herba Menthae; the weight ratio of angelica, notoginseng, salvia miltiorrhiza, polygala tenuifolia, ligusticum wallichii, rhizoma acori graminei, mint, DHA, nervonic acid and vitamin B is 1-30: 1-6; the weight ratio of the total weight of the traditional Chinese medicine composition, the DHA, the nervonic acid and the vitamin B to the guar gum is 100: 5-30. The invention has the following effects: the use is simple and convenient, the cost is low, and the spleen, the stomach, the liver and the kidney of a patient are not damaged; the main components are traditional Chinese medicines, the drug effect can reach the focus of the brain through transdermal absorption at the temple, Baihui acupoint, the neck venous sinus and other parts of the head of a patient, and the traditional Chinese medicine has the effects of improving cerebral circulation, cerebral blood supply and brain functions, promoting blood circulation to remove blood stasis, and inducing resuscitation and restoring consciousness; the method can be used for industrial mass production, is simple and feasible, and has low cost.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an external ointment for treating encephalopathy and a preparation method thereof.
Background
Cerebral infarction is also called ischemic stroke, is a brain disease caused by thrombus blocking cerebral vessels, and has the main symptoms of language disorder, hemiplegia or quadriplegia; the disease is often acute, and mild patients can be cured at the initial stage, but the recurrence rate and the disability rate are high; serious patients may even develop acute coma, death. At present, the number of patients suffering from the disease is more than one thousand in China, and the prevalence rate is the first in the world.
Parkinson is a chronic degenerative brain disease caused by motor neuron disease, and the main symptoms are resting tremor, bradykinesia, hypermyotonia, unstable posture and the like. At present, more than three million patients of the disease exist in China.
Alzheimer's disease, also known as senile dementia, is a chronic degenerative brain disease caused by central neuropathy, and has the main symptoms of progressive memory disorder, cognitive dysfunction, personality change, language disorder and the like. At present, the number of patients suffering from the disease is nearly ten million in China.
Wherein cerebral infarction is also one of the causes of Parkinson's disease and Alzheimer's disease; in addition, no specific medicine exists in the clinic of the Parkinson disease and the Alzheimer disease at present, and long-term medicine taking is needed; in addition, the medical costs of the three diseases are high, which increases the burden on the country and the patients. It is well known that the brain is crucial to people's daily life, and once suffering from the above diseases, the quality of life and normal work of patients are seriously affected.
Disclosure of Invention
In order to solve the above problems, an object of the present invention is to provide an external ointment for treating encephalopathy and a method for preparing the same.
In order to achieve the purpose, the external paste for treating encephalopathy provided by the invention is prepared by boiling a mixture consisting of a traditional Chinese medicine composition, DHA, nervonic acid, vitamin B and guar gum in water; wherein the Chinese medicinal composition comprises radix Angelicae sinensis, Notoginseng radix, Saviae Miltiorrhizae radix, cortex et radix Polygalae, rhizoma Ligustici Chuanxiong, rhizoma Acori Graminei and herba Menthae; the weight ratio of angelica, notoginseng, salvia miltiorrhiza, polygala tenuifolia, ligusticum wallichii, rhizoma acori graminei, mint, DHA, nervonic acid and vitamin B is 1-30: 1-6; the weight ratio of the total weight of the traditional Chinese medicine composition, the DHA, the nervonic acid and the vitamin B to the guar gum is 100: 5-30.
The preparation method of the external ointment for treating encephalopathy comprises the following steps in sequence:
1) weighing raw materials of angelica sinensis, pseudo-ginseng, salvia miltiorrhiza, polygala tenuifolia, ligusticum wallichii, rhizoma acori graminei, mint, DHA, nervonic acid and vitamin B according to a proportion, preparing the raw materials into raw material powder, and then putting the raw material powder into a container;
2) weighing guar gum according to a proportion, putting the guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 10-20 minutes, and finally concentrating the decoction to the density of 0.8-1.3 to prepare the external ointment for treating encephalopathy.
In the step 1), the fineness of the raw material powder is 50-300 meshes.
The external ointment for treating encephalopathy and the preparation method thereof provided by the invention have the following beneficial effects:
1. the use is simple and convenient, the cost is lower, and the external preparation does not hurt the spleen, the stomach, the liver and the kidney of a patient;
2. the main components are traditional Chinese medicines, the drug effect can reach the focus of the brain through transdermal absorption at the temple, Baihui acupoint, the neck venous sinus and other parts of the head of a patient, and the traditional Chinese medicine has the effects of improving cerebral circulation, cerebral blood supply and brain functions, promoting blood circulation to remove blood stasis, and inducing resuscitation and restoring consciousness;
3. the method can be used for industrial mass production, is simple and feasible, and has low cost.
Detailed Description
The external ointment for treating encephalopathy provided by the invention is suitable for treating cerebral infarction, Parkinson and Alzheimer's disease, but is not suitable for patients who have cerebral hemorrhage and hemorrhagic tendency. The main components of the external ointment have the following effects:
1. pseudo-ginseng, as a messenger drug, has the effects of promoting blood circulation, removing blood stasis and improving blood circulation;
2. the salvia miltiorrhiza is a ministerial drug and has the effects of promoting blood circulation, removing blood stasis and improving blood circulation;
3. the angelica is a monarch drug and has the effects of enriching and activating blood and improving blood circulation;
4. the polygala root is a ministerial drug and has the effects of soothing nerves, benefiting intelligence, eliminating phlegm and reducing swelling;
5. rhizoma acori graminei is used as a guiding drug and has the effects of inducing resuscitation and restoring consciousness;
6. the ligusticum wallichii is an adjuvant drug and has the effects of promoting blood circulation, promoting qi circulation and promoting blood circulation;
7. the mint is an adjuvant drug and has the effects of cooling, relieving exterior syndrome, inducing resuscitation and restoring consciousness;
DHA, commonly known as brain gold, is an important unsaturated fatty acid for brain, and can enhance memory and intelligence;
9. nervonic acid, an important and essential nutrient component of brain cells, repairs injured nervous tissues;
10. vitamin B, which contains various nutrient components required by nerve cells;
the present invention will be described in detail with reference to specific examples.
Example 1:
the preparation method of the external ointment for treating encephalopathy provided by the embodiment comprises the following steps in sequence:
1) weighing 20 parts of angelica, 10 parts of pseudo-ginseng, 20 parts of salvia miltiorrhiza, 20 parts of polygala tenuifolia, 10 parts of ligusticum wallichii, 10 parts of rhizoma acori graminei, 6 parts of mint, 6 parts of DHA, 6 parts of nervonic acid and 6 parts of vitamin B as raw materials in proportion, and then putting the raw materials into a container;
2) putting 20 parts of guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 20 minutes, finally concentrating the decoction to the density of 1.3, and cooling to obtain the external ointment for treating encephalopathy.
Example 2:
the preparation method of the external ointment for treating encephalopathy provided by the embodiment comprises the following steps in sequence:
1) weighing 15 parts of angelica, 10 parts of pseudo-ginseng, 15 parts of salvia miltiorrhiza, 15 parts of polygala tenuifolia, 10 parts of ligusticum wallichii, 10 parts of rhizoma acori graminei, 4 parts of mint, 4 parts of DHA, 4 parts of nervonic acid and 4 parts of vitamin B as raw materials in proportion, and then putting the raw materials into a container;
2) putting 15 parts of guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 20 minutes, finally concentrating the decoction to the density of 1.2, and cooling to obtain the external ointment for treating encephalopathy.
Example 3:
the preparation method of the external ointment for treating encephalopathy provided by the embodiment comprises the following steps in sequence:
1) weighing 10 parts of angelica, 5 parts of pseudo-ginseng, 10 parts of salvia miltiorrhiza, 10 parts of polygala tenuifolia, 5 parts of ligusticum wallichii, 5 parts of rhizoma acori graminei, 2 parts of mint, 2 parts of DHA, 2 parts of nervonic acid and 2 parts of vitamin B as raw materials in proportion, and then putting the raw materials into a container;
2) putting 10 parts of guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 20 minutes, finally concentrating the decoction to the density of 1.1, and cooling to obtain the external ointment for treating encephalopathy.
Example 4:
the preparation method of the external ointment for treating encephalopathy provided by the embodiment comprises the following steps in sequence:
1) weighing 30 parts of angelica, 10 parts of pseudo-ginseng, 15 parts of salvia miltiorrhiza, 15 parts of polygala tenuifolia, 15 parts of ligusticum wallichii, 10 parts of rhizoma acori graminei, 6 parts of mint, 4 parts of DHA, 4 parts of nervonic acid and 4 parts of vitamin B as raw materials in proportion, and then putting the raw materials into a container;
2) putting 20 parts of guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 20 minutes, finally concentrating the decoction to the density of 1.0, and cooling to obtain the external ointment for treating encephalopathy.
Example 5:
the preparation method of the external ointment for treating encephalopathy provided by the embodiment comprises the following steps in sequence:
1) weighing 5 parts of angelica, 5 parts of pseudo-ginseng, 5 parts of salvia miltiorrhiza, 5 parts of polygala tenuifolia, 2 parts of ligusticum wallichii, 2 parts of rhizoma acori graminei, 2 parts of mint, 2 parts of DHA, 4 parts of nervonic acid and 4 parts of vitamin B which are taken as raw materials according to a proportion, and then putting the raw materials into a container;
2) putting 20 parts of guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 20 minutes, finally concentrating the decoction to the density of 1.3, and cooling to obtain the external ointment for treating encephalopathy.
Clinical experiments are as follows:
1. the patient Li Shi, 85 years old, suffered from Parkinson and mild cerebral infarction, and frequently pressed the wrong switch in daily life. The inventor pastes the external ointment for treating encephalopathy prepared in the embodiment on the temple, Baihui acupoint, neck venous sinus and other parts of the head of a patient by using non-woven fabrics or gauze as a carrier, and pastes the ointment for treating encephalopathy on the parts for about 10 hours every day, so that after one month of treatment, the limb actions of the patient are obviously improved, and the patient does not press a wrong switch.
2. The patient is Zhangyi, 61 years old, has Alzheimer's disease and poor memory in daily life. The external ointment for treating encephalopathy prepared in the embodiment is pasted on the temple, baihui acupoint, neck venous sinus and other parts of the head of a patient by using non-woven fabrics or gauze as a carrier, the paste is pasted for about 7-8 hours every day, and after one month of treatment, the memory of the patient is obviously improved, so that the condition deterioration can be delayed.
3. The patient is suffered from cerebral infarction and is often forgotten due to poor memory in daily life after being suffered from certain disease and 72 years old. The external ointment for treating encephalopathy prepared in the embodiment is pasted on the temple, baihui acupoint, neck venous sinus and other parts of the head of a patient by using non-woven fabrics or gauze as a carrier, and is pasted for about 7-8 hours every day, so that after one month of treatment, the mind of the patient becomes clear, and the memory is obviously improved.
4. The patient is Wangzhi, is 68 years old, suffers from Parkinson, and often has symptoms of tremor of limbs, bradykinesia and the like in daily life. The external ointment for treating encephalopathy prepared by the embodiment is pasted on the temple, baihui acupoint, neck venous sinus and other parts of the head of a patient by using non-woven fabrics or gauze as a carrier, the paste is pasted for about 6-7 hours every day, and the self-control capability of the limbs of the patient is obviously improved after one month of treatment, so that the disease deterioration can be delayed.
5. The inventor pastes the externally-applied ointment for treating encephalopathy prepared in the embodiment on the temple, baihui acupoint, neck venous sinus and other parts of the head of a patient by using non-woven fabrics or gauze as a carrier, and pastes the externally-applied ointment for treating encephalopathy on the parts of the head of the patient for about 7-8 hours every day, so that the memory of the patient is obviously improved after one month of treatment, the thought is clearer, and the activity limitation is also improved.
Tests of more than 20 patients prove that the external ointment for treating encephalopathy provided by the invention has obvious curative effects on improving cerebral circulation and cerebral function of patients, obviously delays the deterioration of diseases, and has a total effective rate of 75%, so that the external ointment can help the patients to regain life confidence.
Claims (3)
1. An external ointment for treating encephalopathy, which is characterized in that: the external paste for treating encephalopathy is prepared by decocting a mixture consisting of a traditional Chinese medicine composition, DHA, nervonic acid, vitamin B and guar gum with water; wherein the Chinese medicinal composition comprises radix Angelicae sinensis, Notoginseng radix, Saviae Miltiorrhizae radix, cortex et radix Polygalae, rhizoma Ligustici Chuanxiong, rhizoma Acori Graminei and herba Menthae; the weight ratio of angelica, notoginseng, salvia miltiorrhiza, polygala tenuifolia, ligusticum wallichii, acorus gramineus soland, mint, DHA, nervonic acid and vitamin B is 1-30: 1-6; the weight ratio of the total weight of the traditional Chinese medicine composition, the DHA, the nervonic acid and the vitamin B to the guar gum is 100: 5-30.
2. A method for preparing the external ointment for treating encephalopathy of claim 1, which comprises: the preparation method comprises the following steps which are carried out in sequence:
1) weighing raw materials of angelica sinensis, pseudo-ginseng, salvia miltiorrhiza, polygala tenuifolia, ligusticum wallichii, rhizoma acori graminei, mint, DHA, nervonic acid and vitamin B according to a proportion, preparing the raw materials into raw material powder, and then putting the raw material powder into a container;
2) weighing guar gum according to a proportion, putting the guar gum into a container, and uniformly mixing all the raw materials in the container;
3) adding water into a container until the raw materials are completely immersed, then heating and decocting for 10-20 minutes, and finally concentrating the decoction to the density of 0.8-1.3 to prepare the external ointment for treating encephalopathy.
3. The method for preparing an external ointment for treating encephalopathy according to claim 2, characterized in that: in the step 1), the fineness of the raw material powder is 50-300 meshes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210145400.6A CN114432391A (en) | 2022-02-17 | 2022-02-17 | A topical unguent for treating encephalopathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210145400.6A CN114432391A (en) | 2022-02-17 | 2022-02-17 | A topical unguent for treating encephalopathy and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114432391A true CN114432391A (en) | 2022-05-06 |
Family
ID=81373435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210145400.6A Pending CN114432391A (en) | 2022-02-17 | 2022-02-17 | A topical unguent for treating encephalopathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114432391A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025030A (en) * | 2015-09-14 | 2018-05-11 | 莫里艾克私人有限公司 | It is used to prepare the method for herb extracts |
| CN109010703A (en) * | 2018-10-24 | 2018-12-18 | 云南中医学院 | A kind of dispersing liver and promoting blood circulation pharmaceutical composition and its application |
| CN111617135A (en) * | 2020-06-09 | 2020-09-04 | 周迅 | A Chinese medicinal composition for treating senile dementia of early and middle stages, and its preparation method |
-
2022
- 2022-02-17 CN CN202210145400.6A patent/CN114432391A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025030A (en) * | 2015-09-14 | 2018-05-11 | 莫里艾克私人有限公司 | It is used to prepare the method for herb extracts |
| CN109010703A (en) * | 2018-10-24 | 2018-12-18 | 云南中医学院 | A kind of dispersing liver and promoting blood circulation pharmaceutical composition and its application |
| CN111617135A (en) * | 2020-06-09 | 2020-09-04 | 周迅 | A Chinese medicinal composition for treating senile dementia of early and middle stages, and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 周建英等: "益气复智颗粒对多发性梗塞性痴呆模型一氧化氮、内皮素含量的影响", 《浙江中医学院学报》 * |
| 陈大舜等: "《最好的中医名著公开课 名师解读历代名医临床必读医论》", 31 August 2014 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1257722A (en) | Medicinal oil for dredging channels and collaterals of heart and brain and its preparing process | |
| CN102416071B (en) | Medicinal composition with effect of treating insomnia, preparation method and application of medicinal composition | |
| CN101698026B (en) | Method for producing traditional Chinese medicine formula for treating eye disease of amblyopia | |
| CN113332388A (en) | Essential oil for soothing nerves and helping sleep and using method | |
| CN110496157B (en) | Safflower Xiaoyao preparation for treating breast cancer and preparation method and application thereof | |
| CN103816462A (en) | Traditional Chinese medicine for treating hemiplegia | |
| CN114432391A (en) | A topical unguent for treating encephalopathy and preparation method thereof | |
| CN1785370A (en) | Medicine for treating facial paralysis spasm | |
| CN101284084A (en) | Externally used Chinese medicine for curing hyperosteogeny and protrusion of lumbar intervertebral discs | |
| CN1035743C (en) | Preparation method of scar-treating medicine | |
| CN101134087A (en) | Traditional Chinese medicine for treating ischemic stroke | |
| CN101391044A (en) | External traditional Chinese medicine for treating zoster, herpes simplex or the other viral disease and preparation method thereof | |
| CN114306436A (en) | A Chinese medicinal composition cataplasma for treating osteoarticular pain and preparation method thereof | |
| CN103505639A (en) | Parkinson's disease treatment traditional Chinese medicine composition and preparation method thereof | |
| Cheng et al. | Progress in research on acupuncture treatment of senile dementia | |
| CN1025774C (en) | Special "shanhaidan" and its production method | |
| CN101129637A (en) | Traditional Chinese Medicine for Treating Vascular Headache | |
| CN115068541A (en) | A topical Chinese medicinal balm containing aromatic essential oil with blood pressure lowering effect | |
| CN111939198B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and preparation method and application thereof | |
| CN112386658B (en) | Traditional Chinese medicine composition for treating stroke, blood circulation promoting and vein relaxing pill and preparation method | |
| CN115501267A (en) | Application of salvia miltiorrhiza-ligusticum chuanxiong hort composite preparation in preparation of medicine for treating nerve injury | |
| CN1110173A (en) | Jiuxin Yidiling liquid medicine for curing heart disease | |
| CN1053813C (en) | Intelligence-increasing health-care medicinal core and its preparation method | |
| CN116036197A (en) | A Chinese medicinal concentrated pill for treating drug addiction | |
| CN115120652A (en) | Capsule for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |